Tofacitinib for the treatment of tumor necrosis factor-α inhibitor refractory esophageal Crohn’s disease: a case report

BACKGROUND: Esophageal Crohn’s disease is reported as a rare manifestation, although its prevalence may be underestimated because upper endoscopies are not routinely performed in asymptomatic adults. Tofacitinib, an oral janus kinase inhibitor, is a new biologic that has shown promise in the treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Nathoo, Sunina, Hood, William A., Keihanian, Sara, Collinsworth, Amy L., Glover, Sarah C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034573/
https://www.ncbi.nlm.nih.gov/pubmed/27663846
http://dx.doi.org/10.1186/s13256-016-1036-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034573/
https://www.ncbi.nlm.nih.gov/pubmed/27663846
http://dx.doi.org/10.1186/s13256-016-1036-y

Ejemplares similares